Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
We report 4 cases of invasive zygomycosis in hematopoietic stem cell transplant recipients, all occurring after May 2003, when voriconazole began to be used as antifungal prophylaxis. No cases of zygomycosis had been detected in this population in the 3 years prior to May 2003. All 4 patients were receiving immunosuppressive therapy for presumed graft-versus-host disease. Profoundly immunosuppressed patients receiving voriconazole prophylaxis remain at risk for less-common pathogens that are intrinsically resistant to this agent.
Siwek
Greg T
GT
Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA.
Dodgson
Kirsty J
KJ
de Magalhaes-Silverman
Margarida
M
Bartelt
Luther A
LA
Kilborn
Sara B
SB
Hoth
Peter L
PL
Diekema
Daniel J
DJ
Pfaller
Michael A
MA
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D005260:Female; D005658:Fungi / Q000187:drug effects* / Q000302:isolation & purification*; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012233:Rhizopus / Q000187:drug effects* / Q000302:isolation & purification*; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole; D020096:Zygomycosis / Q000453:epidemiology* / Q000517:prevention & control*
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole